Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT02177370
RespimatĀ® Inhaler vs a Metered Dose Inhaler Using BerodualĀ® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: BerodualĀ® RespimatĀ®, low inspiratory flow rateDrug: BerodualĀ® RespimatĀ®, medium inspiratory flow rateDrug: BerodualĀ® RespimatĀ®, high inspiratory flow rateDrug: BerodualĀ® HFA-MDI, low inspiratory flow rateDrug: BerodualĀ® HFA-MDI, medium inspiratory flow rateDrug: BerodualĀ® HFA-MDI, high inspiratory flow rate
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02176200
Safety, Tolerability and Efficacy of MicardisĀ® in Patients With Essential Hypertension
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19870
- Registration Number
- NCT02176850
Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: inhaled bronchodilator
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2639
- Registration Number
- NCT02176564
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 491
- Registration Number
- NCT02177435
BIBR 277 Capsule in Patients With Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Drug: BIBR277 low doseDrug: BIBR277 medium doseDrug: BIBR277 high doseDrug: Placebo matching BIBR277
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 225
- Registration Number
- NCT02177448
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02176512
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENTĀ® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDrug: Low dose of Ipratropium bromideDrug: High dose of Ipratropium bromide
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 646
- Registration Number
- NCT02177344
BerodualĀ® RespimatĀ® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease
Phase 3
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: BerodualĀ® RespimatĀ® inhalerDrug: BerodualĀ® metered dose inhaler
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02176187
Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects
Phase 1
Withdrawn
- Conditions
- Healthy
- Interventions
- Drug: BI 691751 fastedDrug: BI 691751 after high fat breakfast
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02175238
- Locations
- šŗšø
1334.28.01001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States